

**PATENT**  
Attorney Docket No. **DHI-06207**

### AMENDMENTS TO THE SPECIFICATION

**Replace the paragraph beginning at page 25, line 11, which starts with "While the invention is illustrated" with the following amended paragraph:**

While the invention is illustrated using the exemplary transgenic BGMK-hDAF cells ~~which will be deposited as ATCC # (ATCC # PTA-4594)~~, and by the exemplary transgenic CV-1-hDAF cells ~~which will be deposited as ATCC #~~, it is expressly contemplated that the invention is not limited to these particular cell types. Rather, the invention contemplates within its scope any cell line which is established from the transgenic cell line designated herein as BGMK-hDAF cells ~~which will be deposited as ATCC # (ATCC # PTA-4594)~~. Further, the invention also contemplates within its scope any cell line which is established from the transgenic cell line designated herein as CV-1-hDAF cells ~~which will be deposited as ATCC #~~.

**Replace the paragraph beginning at page 25, line 20, which starts with "The term 'established from'" with the following amended paragraph:**

The term "established from" when made in reference to a cell line in relation either to the transgenic cell line designated BGMK-hDAF ~~which will be deposited as ATCC # (ATCC # PTA-4594)~~, or to the transgenic cell line designated CV-1-hDAF ~~which will be deposited as ATCC #~~, refers to a cell line which has been obtained (*e.g.*, isolated, purified, *etc.*) either from the transgenic cell line designated BGMK-hDAF ~~which will be deposited as ATCC # (ATCC # PTA-4594)~~, or from the transgenic cell line designated CV-1-hDAF ~~which will be deposited as ATCC #~~, respectively, using any manipulation, such as, without limitation, infection with virus, transfection with DNA sequences, treatment and/or mutagenesis using for example chemicals, radiation, *etc.*, selection of any cell that is contained in the transgenic cell line designated BGMK-hDAF, *etc.* For example, a cell line established from the transgenic cell line designated BGMK-hDAF includes BGMK-hDAF cells which have been treated with chemical compounds [*e.g.*, *N*-ethyl-*N*-nitrosourea (ENU), methylnitrosourea (MNU), procarbazine hydrochloride (PRC), triethylene melamine (TEM), acrylamide monomer (AA), chlorambucil (CHL), melphalan (MLP), cyclophosphamide (CPP), diethyl sulfate (DES), ethyl methane sulfonate (EMS), methyl methane sulfonate (MMS), 6-mercaptopurine (6MP), mitomycin-C (MMC), procarbazine (PRC), *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG), <sup>3</sup>H<sub>2</sub>O, and urethane (UR)], and electromagnetic radiation [*e.g.*, X-ray radiation, gamma-radiation, ultraviolet light].

**PATENT**  
Attorney Docket No. **DHI-06207**

**Replace the paragraph beginning at page 30, line 9, which starts with "The term 'cell type' with the following amended paragraph:**

The term "cell type other than the transgenic buffalo green monkey kidney cell line" as used herein includes, without limitation, the BGMK cell line from Diagnostic Hybrids, Inc., catalog # 53; any cell type which is established from a cell type other than the BGMK cell line from ~~Diagnostic~~ Diagnostic Hybrids, Inc., catalog # 53; and any cell type established from the BGMK-hDAF cell line ~~which will be deposited as ATCC#~~ (ATCC # PTA-4594). In particular, the term "cell type other than the transgenic buffalo green monkey kidney cell line" expressly includes CV-1 cells which either have not been transfected with the hDAF gene, or which have been transfected with a transgene containing one or more nucleotide sequences of interest. Also, the term "cell type other than the transgenic buffalo green monkey kidney cell line" expressly includes BGMK cells (Diagnostic Hybrids, Inc., catalog # 53) which either have not been transfected with the hDAF gene, or which have been transfected with a transgene containing one or more nucleotide sequences of interest. Further, the term "cell type other than the transgenic buffalo green monkey kidney cell line" expressly includes BGMK-hDAF cells ~~which will be deposited as ATCC#~~ and (ATCC # PTA-4594) which have additionally been transfected with a transgene containing one or more nucleotide sequences of interest.

**Replace the paragraph beginning at page 30, line 25, which starts with "The term 'cell type' with the following amended paragraph:**

The term "cell type other than the transgenic ~~African~~ African green monkey kidney cell line" as used herein includes, without limitation, the CV-1 cell line (ATCC #CCL 70); any cell type which is established from a cell type other than the CV-1 cell line (ATCC #CCL 70); and any cell type established from the CV-1-hDAF cell line ~~which will be deposited as ATCC#~~. In particular, the term "cell type other than the transgenic African green monkey kidney cell line" expressly includes CV-1 cells which either have not been transfected with the hDAF gene, or which have been transfected with a transgene containing one or more nucleotide sequences of interest. This term also expressly includes BGMK cells (Diagnostic Hybrids, Inc., catalog # 53) which either have not been transfected with the hDAF gene, or which have been transfected with a transgene containing one or more nucleotide sequences of interest. Further, the term "cell type other than the transgenic ~~Green~~ African green monkey kidney cell line" expressly includes CV-1-

**PATENT**  
Attorney Docket No. **DHI-06207**

hDAF cells ~~which will be deposited as ATCC#~~ and which have additionally been transfected with a transgene containing one or more nucleotide sequences of interest.

Respectfully submitted:

Dated: August 10, 2004

Mahattamdan

Maha A. Hamdan  
Registration No. 43,655  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
(415) 904-6500